NovaDel genitourinary, drug delivery news
NovaDel said it is continuing to seek strategic alternatives for the company, including raising capital or a sale of the company or its assets. The company said it believes it will not have enough cash to continue operations after the end of January. NovaDel said it plans to file for bankruptcy if it does not complete a financing or sale of the company or its assets. In August, NovaDel said its ability to market Duromist in the U.S. may be limited until 2019 after a judge in the U.S. District Court for the Eastern District of Virginia upheld the validity of a U.S. patent covering the use of erectile dysfunction (ED) drug Viagra sildenafil from Pfizer Inc. (NYSE:PFE, New York, N.Y.). Duromist is an oral spray formulation of sildenafil (see BioCentury, Sept. 5, 2011). ...